Trials / Completed
CompletedNCT04854980
Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients
Serologic Response to the SARS-CoV-2 MRNA-1273 Vaccine in Select Subsets of Oncology Patients - a Pilot Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 8 (actual)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To explore the immune response to the COVID-19 vaccine in cancer patients and compare to the general population.
Detailed description
The purpose of this study is to measure the immune response to the COVID-19 vaccine in cancer patients and compare to the general population. This information can help optimize the timing of the mRNA-1273 vaccine relative to starting treatment for cancer, adding booster immunizations or incorporation of medications that to enhance the immune response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood Sample | Blood sample, 2- to 5 tea spoon full (between 10 to 25 mL approximately) between 43 to 96 days after first dose of the vaccine. |
Timeline
- Start date
- 2021-08-03
- Primary completion
- 2022-03-15
- Completion
- 2024-07-23
- First posted
- 2021-04-22
- Last updated
- 2025-03-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04854980. Inclusion in this directory is not an endorsement.